Company Description
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use.
It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer’s disease, Parkinson’s diseases.
The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells.
It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.
Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
| Country | United States |
| Founded | 1989 |
| IPO Date | Jan 21, 1997 |
| Industry | Medical Care Facilities |
| Sector | Healthcare |
| Employees | 88 |
| CEO | David I. Portnoy |
Contact Details
Address: 700 Brooker Creek Boulevard, Suite 1800 Oldsmar, Florida 34677 United States | |
| Phone | 813 749 2100 |
| Website | cryo-cell.com |
Stock Details
| Ticker Symbol | CCEL |
| Exchange | NYSEAMERICAN |
| Fiscal Year | December - November |
| Reporting Currency | USD |
| CIK Code | 0000862692 |
| CUSIP Number | 228895108 |
| ISIN Number | US2288951088 |
| Employer ID | 22-3023093 |
| SIC Code | 8090 |
Key Executives
| Name | Position |
|---|---|
| Mark L. Portnoy | Co-Chief Executive Officer and Director |
| David I. Portnoy | Chairman and Co-Chief Executive Officer |
| Jill M. Taymans | Chief Financial Officer and Vice President of Finance |
| Oleg Mikulinsky | Chief Information Officer |
| Dr. Joanne Kurtzberg M.D. | Medical Director and Member of Medical and Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 17, 2024 | 10-Q/A | [Amend] Quarterly report |
| Oct 17, 2024 | 8-K | Current Report |
| Oct 15, 2024 | 10-Q | Quarterly Report |
| Oct 7, 2024 | ARS | Filing |
| Oct 7, 2024 | DEF 14A | Other definitive proxy statements |
| Sep 17, 2024 | 8-K | Current Report |
| Jul 15, 2024 | 10-Q | Quarterly Report |